GlassScriptPhysician profile
Kenneth V Kall
NPI 1255864880
$5,490.97
in general payments reported to CMS, 2019-2025
32 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $255 · 2021: $584 · 2022: $855 · 2023: $739 · 2024: $1,297 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.84 | 2021-2025 | |
| Novo Nordisk INC | $881.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $789.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $460.06 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.83 | 2019-2025 | Ofev, Jardiance |
| Lilly USA, LLC | $255.95 | 2020-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $213.96 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $208.26 | 2020-2025 | Bexsero, Arexvy, Shingrix |
| Astellas Pharma US INC | $136.77 | 2024-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $132.67 | 2021 | |
| Exact Sciences Corporation | $123.58 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $122.06 | 2024-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $112.59 | 2022-2025 | |
| Celgene Corporation | $106.23 | 2019 | |
| Xeris Pharmaceuticals, INC. | $103.82 | 2024-2025 | Gvoke Hypopen, Recorlev |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $84.18 | 2021-2022 | |
| Amgen INC. | $75.29 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Sanofi Pasteur INC. | $62.56 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.57 | 2022 | |
| Phadia US INC. | $30.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.63 | 2022 | |
| Kyowa Kirin, INC. | $22.58 | 2025 | |
| Dexcom, INC. | $20.86 | 2025 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $20.58 | 2023 | |
| Scpharmaceuticals INC. | $19.50 | 2025 | |
| Organon LLC | $18.49 | 2021 | |
| Dynavax Technologies Corporation | $16.81 | 2022 | |
| Noven Therapeutics, LLC | $16.29 | 2025 | Xelstrym |
| Lundbeck LLC | $15.14 | 2025 | Rexulti |
| Genentech USA, INC. | $13.87 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.